Forum Topics AVR AVR Broker report

Pinned straw:

Last edited 11 months ago

Redemption…?

5043677b8cdb67da364834f543a85563f70477.gif

I refuse to pay for broker content. So instead I’m just wading through a sewer of AI generated garbage — and have probably submitted myself to about a decade of email spam — all in my vain attempts to dig under these paywalls when I should be sleeping.

I’m giving up now, but just FYI the consistencies in the rumours are broker coverage commencing, and price targets (in US dollars) as follows:

  • Cantor Fitzgerald at $9.00;
  • TD Cowen (underwriters of the IPO) at $15.00; and
  • Barclays at $22.00.

Of course, it could all just be in AI BS dollars and I’ve just finally broken my internet with my Anteris monomania. I’ll check the NY closing price when I wake up and see if there was anything in it.

PabloEskyBruh
Added 11 months ago

All three investment houses were behind the IPO and are to some extent obviously selling their book:

44fe17764f82fc5778c9c1870f811d74b3eb8f.jpeg

Matt Miksic (the analyst behind the $22 Anteris price target) also covers Edwards Life Sciences for Barclays.

5c8a4d423617e373b97bc18ed039712e5578ce.jpeg

Mikisic has also recently lowered his target price for Edwards:

https://www.nasdaq.com/articles/analyst-verdict-edwards-lifesciences-eyes-17-experts

Edwards list a further 28 analysts who cover them - participating in the earning calls and writing them up. This med-tech is big business in the US and promises the type of coverage Anteris was never going to receive whilst it remained solely on the ASX.

I think the TD securities stabilisation process (announced daily in ASX announcements with them buying on market under the IPO price of $6 USD) ends shortly (or has already) and now the post-IPO pump can begin.

6
PabloEskyBruh
Added 11 months ago

Finally, something reputable in the form of the Wall Street Journal. Barclays at a low-ball $22:

144a69c55ec18d74a4eb76c5e9e89ce39913bd.png

10
PabloEskyBruh
Added 11 months ago

5d7f8396191c02c95b6b8bac4e91174528a8b0.jpeg

Not huge, but enough of a bump to convince me broker coverage has actually commenced. This is the least spammy article I’ve found so far (but it was a low bar):

https://www.benzinga.com/trading-ideas/movers/25/01/42859544/anteris-technologies-positioned-to-capture-4-5-of-us-transcatheter-valve-replacement-market-by-2030-analyst

I’m expecting more mainstream news articles and perhaps even a company press release in coming days. Could take the Australian market a day or two also to catch up. I think there is a bit of runway left just on this news alone (merely broker coverage commencing), let alone the targets themselves.

13